Company facts
- Headquarters
- Hong Kong
- Most recent report
- 20-F, filed Oct 7, 2026
- Filings on record
- 85 filings
- On EDGAR
- CIK 1829667
- Filer status
- Large accelerated filer
Financials 8 of 40
- 20-F Annual report, foreign issuer Oct 7, 2026
- 6-K Report a foreign issuer made public elsewhere May 22, 2026
- 6-K Report a foreign issuer made public elsewhere May 19, 2026
- 6-K Report a foreign issuer made public elsewhere May 19, 2026
- 6-K Report a foreign issuer made public elsewhere May 8, 2026
- 6-K Report a foreign issuer made public elsewhere Apr 17, 2026
- 6-K Report a foreign issuer made public elsewhere Mar 30, 2026
- 6-K Report a foreign issuer made public elsewhere Mar 30, 2026
Prospectuses and Registrations 6
Ownership 8 of 18
- 4 Insider reported a trade May 29, 2026
- 4 Insider reported a trade May 29, 2026
- 3 Insider reported their initial holding Mar 18, 2026
- 3 Insider reported their initial holding Mar 18, 2026
- 3 Insider reported their initial holding Mar 18, 2026
- 3 Insider reported their initial holding Mar 18, 2026
- 3 Insider reported their initial holding Mar 18, 2026
- 3 Insider reported their initial holding Mar 18, 2026
Other 8 of 21
- F-3ASR Mar 30, 2026
- EFFECT Notice that a registration became effective Jul 15, 2021
- CERT Exchange certified a listing Jul 15, 2021
- 8-A12B Registration of a security for exchange listing Jul 15, 2021
- CORRESP Reply to SEC staff Jul 13, 2021
- CORRESP Reply to SEC staff Jul 13, 2021
- F-1/A Registration statement, foreign issuer, amended Jun 23, 2021
- CORRESP Reply to SEC staff Jun 22, 2021
Everything here comes from Regencell Bioscience Holdings Ltd's own filings on SEC EDGAR. The filing list is rechecked every hour.